Enzon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Revenue	-	0.03	-	0.03	0.7	Upgrade
Revenue Growth (YoY)	-	-	-	-96.29%	1248.08%	Upgrade
Gross Profit	-	0.03	-	0.03	0.7	Upgrade
Selling, General & Admin	1.36	1.35	1.04	1.06	1.17	Upgrade
Operating Expenses	1.36	1.35	1.04	1.06	1.17	Upgrade
Operating Income	-1.36	-1.33	-1.04	-1.03	-0.47	Upgrade
Interest & Investment Income	1.92	2.45	2.26	0.65	0.01	Upgrade
EBT Excluding Unusual Items	0.57	1.13	1.22	-0.39	-0.46	Upgrade
Merger & Restructuring Charges	-3.96	-	-	-	-	Upgrade
Pretax Income	-3.39	1.13	1.22	-0.39	-0.46	Upgrade
Income Tax Expense	0.02	0.35	-0.16	-0.2	0.01	Upgrade
Net Income	-3.41	0.78	1.37	-0.19	-0.47	Upgrade
Preferred Dividends & Other Adjustments	2.12	1.28	1.28	1.28	2.02	Upgrade
Net Income to Common	-5.53	-0.5	0.1	-1.46	-2.49	Upgrade
Net Income Growth	-	-43.34%	-	-	-	Upgrade
Shares Outstanding (Basic)	74	74	74	74	74	Upgrade
Shares Outstanding (Diluted)	74	74	74	74	74	Upgrade
Shares Change (YoY)	-	-	-	-	45.23%	Upgrade
EPS (Basic)	-0.07	-0.01	0.00	-0.02	-0.03	Upgrade
EPS (Diluted)	-0.07	-0.01	0.00	-0.02	-0.03	Upgrade
Gross Margin	-	100.00%	-	100.00%	100.00%	Upgrade
Operating Margin	-	-5103.85%	-	-3969.23%	-66.90%	Upgrade
Profit Margin	-	-1911.54%	-	-5619.23%	-355.49%	Upgrade
EBIT	-1.36	-1.33	-1.04	-1.03	-0.47	Upgrade
EBIT Margin	-	-	-	-	-66.90%	Upgrade
Effective Tax Rate	-	30.84%	-	-	-	Upgrade
Revenue as Reported	-	0.03	-	0.03	0.7	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.